Abstract
Despite advances in surgery and drug discovery, brain tumors remain fatal diseases. Early detection and diagnosis of brain tumors is of great importance for improving treatment outcomes. Magnetic resonance imaging (MRI) is a prominent, clinically-relevant imaging modality because of its excellent tissue contrast resolution, direct multiplanar imaging and increased sensitivity to edema. MRI utility is further enhanced with the use of magnetic iron oxide nanoparticles, which can function as both a contrast agent for imaging and as a drug delivery vehicle for treating brain cancer. In this review, the principles of various imaging modalities for brain tumors are discussed with focus on monocrystalline iron oxide nanoparticle (MION)-based MRI contrast agents. A summary is given on the mechanism of contrast effect, magnetophoretic mobility and magnetic retention, and strategies to enhance tumor selectivity, increase spatial resolution and reduce nonspecific uptake of MION.
Keywords: Brain tumors, imaging, MRI, iron oxide nanoparticles, targeting, iron oxide nanoparticles, drug discovery, magnetic iron oxide nanoparticles, treating brain cancer, oxide nanoparticle (MION)-based, Brain cancers, metastatic brain tumor, solid tumor cancer, glioblastoma multiforme (GBM)
Current Pharmaceutical Biotechnology
Title:Magnetic Nanoparticles for MRI of Brain Tumors
Volume: 13 Issue: 12
Author(s): Jianxin Wang, Yongzhuo Huang, Allan E. David, Beata Chertok, Lei Zhang, Faquan Yu and Victor C. Yang
Affiliation:
Keywords: Brain tumors, imaging, MRI, iron oxide nanoparticles, targeting, iron oxide nanoparticles, drug discovery, magnetic iron oxide nanoparticles, treating brain cancer, oxide nanoparticle (MION)-based, Brain cancers, metastatic brain tumor, solid tumor cancer, glioblastoma multiforme (GBM)
Abstract: Despite advances in surgery and drug discovery, brain tumors remain fatal diseases. Early detection and diagnosis of brain tumors is of great importance for improving treatment outcomes. Magnetic resonance imaging (MRI) is a prominent, clinically-relevant imaging modality because of its excellent tissue contrast resolution, direct multiplanar imaging and increased sensitivity to edema. MRI utility is further enhanced with the use of magnetic iron oxide nanoparticles, which can function as both a contrast agent for imaging and as a drug delivery vehicle for treating brain cancer. In this review, the principles of various imaging modalities for brain tumors are discussed with focus on monocrystalline iron oxide nanoparticle (MION)-based MRI contrast agents. A summary is given on the mechanism of contrast effect, magnetophoretic mobility and magnetic retention, and strategies to enhance tumor selectivity, increase spatial resolution and reduce nonspecific uptake of MION.
Export Options
About this article
Cite this article as:
Wang Jianxin, Huang Yongzhuo, E. David Allan, Chertok Beata, Zhang Lei, Yu Faquan and C. Yang Victor, Magnetic Nanoparticles for MRI of Brain Tumors, Current Pharmaceutical Biotechnology 2012; 13 (12) . https://dx.doi.org/10.2174/138920112803341824
DOI https://dx.doi.org/10.2174/138920112803341824 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Agents in CNS Myeloma Treatment
Central Nervous System Agents in Medicinal Chemistry Targeting Aberrant TGF-β Signaling in Pre-Clinical Models of Cancer
Anti-Cancer Agents in Medicinal Chemistry Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets Inflammation and Chronic Oxidative Stress in Radiation-Induced Late Normal Tissue Injury: Therapeutic Implications
Current Medicinal Chemistry Chronic Inflammation and Colorectal Cancer: The Role of Vascular Endothelial Growth Factor
Current Pharmaceutical Design Histone Modifications as Molecular Targets in Nasopharyngeal Cancer
Current Medicinal Chemistry The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations
Current Cancer Drug Targets The Potency of Refined Mouse Models: Implications for Clinical Trials
Current Cancer Therapy Reviews The Interactions of Anti-Cancer Drugs Approved in the Last Decade in the United States with Membrane Transporters
Anti-Cancer Agents in Medicinal Chemistry The Role of Ghrelin Signals in Breast Cancer- A Systematic Review
Current Signal Transduction Therapy Combinatorial Nanoparticles for Cancer Diagnosis and Therapy
Current Medicinal Chemistry Gene Therapy Using an Adenovirus Vector for Apoptosis-Related Genes is a Highly Effective Therapeutic Modality for Killing Glioma Cells
Current Gene Therapy State-of-the-Art Methodologies for the Discovery and Characterization of DNA G-Quadruplex Binders
Current Pharmaceutical Design Drug-Lipid Membrane Interaction Mechanisms Revealed Through Molecular Simulations
Current Physical Chemistry Role of Tumor Microenvironment in Cancer Stem Cells Resistance to Radiotherapy
Current Cancer Drug Targets Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies
Anti-Cancer Agents in Medicinal Chemistry Manipulation and Engineering of Metabolic and Biosynthetic Pathway of Plant Polyphenols
Current Pharmaceutical Design Poly (Lactic-co-Glycolic Acid) & Tocopheryl Polyethylene Glycol Succinate Nanoparticles for the Treatment of Different Brain Cancers
Anti-Cancer Agents in Medicinal Chemistry Identification of Disease-Relevant Genes for Molecularly-Targeted Drug Discovery
Current Cancer Drug Targets